Perspective Therapeutics partners with Merck to test [212Pb]PSV359 with Keytruda in FAP-α-positive solid tumors
Reuters2026/09/14 10:16- Perspective Therapeutics entered a clinical trial collaboration and supply agreement with Merck to test [212Pb]PSV359 with Keytruda (pembrolizumab).
- Combination will be evaluated via an amendment to Perspective’s ongoing Phase 1/2a study in FAP-α-positive non-small cell lung cancer and colorectal cancer.
- Merck will supply pembrolizumab at no cost; Perspective will sponsor the trial.
- Study has completed enrollment in the first three monotherapy dose cohorts.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
MSC Industrial Direct CFO Robert M. Kuhns files initial beneficial ownership statement
Bank of America plunges 6%! CEO says Q3 trading revenue is flat and investment banking income falls short of expectations
Bank of America CEO Brian Moynihan stated that the bank's trading revenue this quarter will be "relatively flat" compared to the third quarter last year, in contrast to the surge in revenue experienced on Wall Street during the first half of this year. He also expects investment banking fees to be between $1.6 billion and $1.8 billion, falling short of the market's expectation of nearly $2 billion.
10-Year Treasury Yield Touches 5%, Pushed by Oil Surge-- WSJ
8 Major Banking Institutions Issue Strong Statement Against Clarity Act, the Bullish Cryptocurrency Act
Crypto prices
More
